-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BLzxBzyHt5Sqysj/YvanuWL85LMvXNSXq33RqazBFsKm02l1vqp40JOapDA/8wY0 Tj7Bi+mcygwDsomkeri26A== 0000891092-04-005939.txt : 20041214 0000891092-04-005939.hdr.sgml : 20041214 20041214132731 ACCESSION NUMBER: 0000891092-04-005939 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20041214 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20041214 DATE AS OF CHANGE: 20041214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BSD MEDICAL CORP CENTRAL INDEX KEY: 0000320174 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 751590407 STATE OF INCORPORATION: DE FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-10783 FILM NUMBER: 041200912 BUSINESS ADDRESS: STREET 1: 2188 W 2200 SOUTH CITY: SALT LAKE CITY STATE: UT ZIP: 84119 BUSINESS PHONE: 8019725555 MAIL ADDRESS: STREET 1: 2188 WEST STREET 2: 2200 SOUTH CITY: SALT LAKE CITY STATE: UT ZIP: 84119 8-K 1 e20159_8k.txt FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 14, 2004 BSD MEDICAL CORPORATION - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 - -------------------------------------------------------------------------------- (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 2188 West 2200 South Salt Lake City, Utah 84119 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (801) 972-5555 N/A - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) Item 7.01. Regulation FD Disclosure. BSD Medical Corporation issued a press release on December 14, 2004. A copy of the press release is hereby furnished as Exhibit 99.1 attached hereto Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Item 9.01. Financial Statements and Exhibits. (c) Exhibits 99.1 Press Release of BSD Medical Corporation dated December 14, 2004. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 14, 2004 By: /s/ Hyrum A. Mead ---------------------------------- President EX-99.1 2 e20159ex99-1.txt PRESS RELEASE Exhibit 99.1 BSD Medical Opens Chinese Market with First Sale of Advanced Cancer Treatment System SALT LAKE CITY, December 14, 2004--BSD Medical Corp. (OTCBB:BSDM) today announced that it has shipped the first cancer treatment system, a BSD-2000, to its new distributor in the People's Republic of China, Dalian Orientech Co. LTD. The sale opens BSD's market to the world's most populous nation. The BSD-2000 is an advanced cancer treatment system that focuses on and kills cancer, including cancers located deep in the body, using radio frequency (RF) energy. When cancerous cells are superheated they become depleted and die. They also become less resistant to radiation and chemotherapy, and the treatment is used to boost the effectiveness of both. Superheating, or causing hyperthermia in cancerous tissue, is a therapy that has had a following in China historically supported by Chinese manufactured systems. Dalian Orientech controls about 65% of the market, with over 1,500 installed hyperthermia systems. The BSD-2000 fills a demand for high-end capabilities and for American-made products. Their sales force is located in 23 provinces, and is supported by a telephone staff that qualifies and grades potential customers. Dalian Orientech provides technical and service support for all of its customers. Although destined for clinical use, the first BSD-2000 will also be used in a hospital setting to obtain regulatory approval for the BSD-2000 from the Chinese government. In China, regulatory approval normally can be accomplished over several months of testing and review. The demand for medical services is very large in China by Western standards. Some hospitals treat over a million patients a year. While the charge for the medical services required by individual patients is modest, the heavy and efficient utilization created from a large patient volume makes the use of high-end Western medical equipment affordable. BSD Medical Corporation is a leading developer of microwave and radio frequency systems for thermal medicine applicable to the treatment of cancer, benign diseases and other medical conditions. For more information about BSD Medical Corp. and its products visit www.BSDMC.com. Statements contained in this press release that are not historical facts are forward looking-statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include the timing and ultimate regulatory acceptance of the BSD-2000 for use in China, and the future level of acceptance of the BSD-2000 for sales in China. All forward-looking statements are subject to risks and uncertainties, some of which are detailed in part in the Company's filings with the Securities and Exchange Commission. ### -----END PRIVACY-ENHANCED MESSAGE-----